Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
IONS Ionis Pharmaceuticals
- 31.040
- +0.690+2.27%
Close Feb 14 16:00 ET
- 31.040
- 0.0000.00%
Post 20:01 ET
4.90BMarket Cap-12.72P/E (TTM)
31.600High30.370Low1.45MVolume30.490Open30.350Pre Close44.64MTurnover0.92%Turnover RatioLossP/E (Static)157.90MShares52.34052wk High7.40P/B4.86BFloat Cap30.23052wk Low--Dividend TTM156.52MShs Float86.582Historical High--Div YieldTTM4.05%Amplitude2.500Historical Low30.878Avg Price1Lot Size
Ionis Pharmaceuticals News
Earnings Week Ahead: BABA, XYZ, BIDU, WMT, RIVN and More
Earnings Preview: IONS to Report Financial Results Pre-market on February 19
Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently
Why Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to Analysts
Press Release: Ionis to Hold Fourth Quarter and Full Year 2024 Financial Results Webcast
Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed
Novartis Delays Phase 3 Readout for Ionis Heart Drug
Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment
Express News | FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in Sma
S&P 500 Futures Climb In Premarket Trading; Tempus AI, IDACORP Lead
Ionis Pharmaceuticals Insider Sold Shares Worth $1,091,444, According to a Recent SEC Filing
Insider Sale: EVP Research of $IONS (IONS) Sells 7,154 Shares
Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock With Biggest Upside Potential
Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51
Ionis Pharmaceuticals (IONS) Gets a Hold From Bernstein
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
Ionis Pharmaceuticals Analyst Ratings
RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70
RBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $67
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.